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HIV-infected individuals are at high risk of tuberculosis disease and those with
prior tuberculosis episodes are at even higher risk of disease recurrence. A non-
sputum biomarker that identifies individuals at highest tuberculosis risk would allow
targeted microbiological testing and appropriate treatment and also guide need for
prolonged therapy. We determined the utility of a previously developed whole blood
transcriptomic correlate of risk (COR) signature for (1) predicting incident recurrent
tuberculosis, (2) tuberculosis diagnosis and (3) its potential utility for tuberculosis
treatment monitoring in HIV-infected individuals. We retrieved cryopreserved blood
specimens from three previously completed clinical studies and measured the
COR signature by quantitative microfluidic real-time-PCR. The signature differentiated
recurrent tuberculosis progressors from non-progressors within 3 months of diagnosis
with an area under the Receiver-operating characteristic (ROC) curve (AUC) of
0.72 (95% confidence interval (CI), 0.58–0.85) amongst HIV-infected individuals on
antiretroviral therapy (ART). Twenty-five of 43 progressors (58%) were asymptomatic
at microbiological diagnosis and thus had subclinical disease. The signature showed
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excellent diagnostic discrimination between HIV-uninfected tuberculosis cases and
controls (AUC 0.97; 95%CI 0.94–1). Performance was lower in HIV-infected individuals
(AUC 0.83; 95%CI 0.81–0.96) and signature scores were directly associated with
HIV viral loads. Tuberculosis treatment response in HIV-infected individuals on ART
with a new recurrent tuberculosis diagnosis was also assessed. Signature scores
decreased significantly during treatment. However, pre-treatment scores could not
differentiate between those who became sputum negative before and after 2 months.
Direct application of the unmodified blood transcriptomic COR signature detected
subclinical and active tuberculosis by blind validation in HIV-infected individuals.
However, prognostic performance for recurrent tuberculosis, and performance as
diagnostic and as treatment monitoring tool in HIV-infected persons was inferior to
published results from HIV-negative cohorts. Our results suggest that performance of
transcriptomic signatures comprising interferon stimulated genes are negatively affected
in HIV-infected individuals, especially in those with incompletely suppressed viral loads.
Keywords: tuberculosis, recurrence, diagnosis, treatment, transcriptomic signature, HIV, antiretroviral therapy
INTRODUCTION
Every year more than 10 million people develop tuberculosis
(TB) disease, the leading infectious cause of death (World
Health Organization [WHO], 2017b). Individuals who have had
TB previously are at significantly increased risk of developing
recurrent disease. Incidence of recurrence within the first year
following completion of TB treatment is 2–8% (Friedrich et al.,
2013; Gillespie et al., 2014; Merle et al., 2014), which is several-
fold higher than the rate of incident TB disease in the same
populations with no history of TB. Recurrent TB disease thus
contributes substantially to the significant disease burden in
settings where TB is endemic. A further compounding factor is
underlying HIV infection, which not only increases the risk of TB
in general, but further increases risk of recurrent TB (Korenromp
et al., 2003; Maher et al., 2005). For example, risk of recurrent
TB disease was five times higher in HIV-infected South African
gold miners relative to their HIV-uninfected colleagues (Mallory
et al., 2000). Early and accurate identification of HIV-infected
individuals who are at high risk of recurrent TB would allow
targeted investigation for disease, facilitating earlier provision of
antibiotic treatment.
Several studies have shown that blood transcriptomic
signatures can accurately differentiate between active TB disease,
asymptomatic Mycobacterium tuberculosis (Mtb) infection and
other respiratory diseases such as pneumonia and sarcoidosis,
demonstrating promising diagnostic potential of immune gene
expression in predicting TB (Berry et al., 2010; Maertzdorf
et al., 2012; Bloom et al., 2013; Kaforou et al., 2013; Anderson
et al., 2014; Sweeney et al., 2016). It is likely that such
transcriptomic signatures, which detect inflammatory signals
such as elevated interferon stimulated gene (ISG) expression
commonly associated with TB disease, would also have promising
utility for diagnosing recurrent TB, but to our knowledge this has
yet to be tested.
We recently developed and validated a whole blood
transcriptomic correlate of risk signature [Adolescent Cohort
Study (ACS) COR] for TB comprising 16 ISGs, which showed
prognostic value for incident TB disease in adults and adolescents
from two African countries (Zak et al., 2016). Analysis of the
inflammatory processes underlying TB disease progression
strongly suggests that the COR signature, as well as other
similar transcriptomic signatures, detect incipient or subclinical
disease weeks to months before the manifestation of clinical
symptoms (Scriba et al., 2017; Suliman et al., 2018). We
subsequently reduced the COR signature to an 11-gene signature
to improve laboratory throughput, with no effect on diagnostic
or prognostic performance (Darboe et al., 2018). Despite
strong ISG expression in granulocytes (Berry et al., 2010;
Scriba et al., 2017), diagnostic performance of the signature
in HIV-uninfected adults was not different in cryopreserved
PBMC and matched whole blood (Darboe et al., 2018). This
opened the possibility to evaluate the COR signature in rare
longitudinal cohorts from whom only biobanked PBMCs are
available. In this study we aimed to determine the prognostic
value of this 11-gene COR signature for recurrent TB in people
living with HIV who participated in the “TB Recurrence upon
Treatment with HAART” (TRuTH) study conducted at the
Centre for the Aids Programme of Research In South Africa
(CAPRISA) in Durban, South Africa (Maharaj et al., 2017;
Sivro et al., 2017).
In addition, we aimed to evaluate the utility of the signature
for monitoring treatment response in HIV-infected patients
treated for recurrent TB disease. Standard treatment of drug-
sensitive TB lasts at least 6 months and commonly comprises a
regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol
during the first 2 months followed by isoniazid and rifampicin
for 4 months. Although this strategy has a high success
rate resulting in bacteriological cure in approximately 86%
under routine, programmatic field conditions (World Health
Organization [WHO], 2017b), treatment failure and relapse
are a very significant problem. Treatment success is typically
monitored by detecting sputum conversion (conversion to a
negative bacteriological test), measured by Mtb culture. However,
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2-month sputum culture conversion has a low predictive value
for predicting treatment failure and relapse (Horne et al., 2010).
Clinical trials of short-course TB therapy regimen report high
relapse rates in participants despite high culture conversion
rates after 2 months of therapy (Burman et al., 2006; Gillespie
et al., 2014; Merle et al., 2014). Novel, non-sputum-based tests
that can accurately monitor treatment efficacy, detect treatment
failure and predict relapse are urgently required. Several studies
have shown that blood transcriptomic signatures can be used
to monitor TB treatment since they can indicate resolution of
TB-associated inflammation and ISG expression levels (Berry
et al., 2010; Bloom et al., 2012, 2013; Cliff et al., 2013; Sweeney
et al., 2016). In a recent study of 99 HIV-uninfected drug-
sensitive TB cases on TB treatment, we showed that the
ACS COR signature, measured at treatment baseline, could
differentiate between patients with cure and treatment failure
and could predict treatment outcome (Thompson et al., 2017).
It is currently not known if blood transcriptomic signatures
will similarly, indicate resolution of TB-associated inflammation
in HIV-infected persons or how a previous episode(s) of
TB affects the kinetics of such signatures during treatment.
In the second part of the study, we determined the utility
of the 11-gene ACS COR signature for monitoring HIV-
infected patients treated for recurrent TB disease as part of the
IMPRESS trial, conducted at CAPRISA in Durban, South Africa
(Naidoo et al., 2017).
MATERIALS AND METHODS
Study Populations
Samples collected from participants enrolled into three
previously completed independent clinical studies were included.
Prognostic Cohort
The first was the TB Recurrence upon Treatment with
HAART (TRuTH) CAPRISA 005 study (Maharaj et al., 2017;
Sivro et al., 2017). This prospective cohort study, conducted
between 2009 and 2013, aimed to assess risk factors associated
with progression to recurrent TB disease during a 3-year
longitudinal follow up in HIV-infected persons who began
ART during treatment of the previous TB episode. At
study enrolment and 3-monthly thereafter, participants were
assessed for recurrent TB, and peripheral blood mononuclear
cells (PBMC) cryopreserved. Investigation for TB included
both sputum induction for liquid culture and assessment of
clinical symptoms of TB disease. Additional sputum cultures
and clinical investigations were performed when participants
presented with TB symptoms or abnormal chest x-rays
outside of follow-up time points. Participants who developed
microbiologically-confirmed recurrent TB during follow up
were labeled as progressors, and selected for further analysis.
For each progressor we selected two non-progressors, who
remained TB-free during follow-up, matching for gender and
date (to within a 90-day window) of ART initiation. Time
to recurrent TB disease was calculated for progressors by
subtracting the sample collection date from the date of
recurrent TB diagnosis. For samples from non-progressors
the “time to recurrent TB” derived from their respective
matched progressor, as shown in Figures 2A,B, was assigned.
This “time to recurrent TB” was used where necessary
for comparative longitudinal analyses between progressors
and non-progressors, even though non-progressors did not
develop disease.
Treatment Response Cohort
The second study was the open-label, randomized controlled
trial, “Improving Retreatment Success” (IMPRESS) (Naidoo et al.,
2017). This trial was designed to determine if a moxifloxacin-
containing 24-week regimen, in which moxifloxacin was
substituted for ethambutol, would improve TB retreatment
outcomes relative to the standard TB treatment regimen.
The study started enrolment in November 2013 in Durban,
KwaZulu-Natal, and follow-up ended in July 2017. The trial
enrolled adults with a previous history of TB disease who
received a new diagnosis of drug-sensitive TB by positive Xpert
MTB/RIF (Cepheid) or sputum smear or both. Participants
attended two-weekly visits during the intensive phase of
treatment and monthly visits during the continuous phase.
Sputum samples were collected for culture testing every
2 weeks during the intensive phase of treatment and monthly
thereafter until successful treatment completion. Whole blood
was collected in PAXgene tubes (Qiagen) at baseline, 2, 6,
8, and 14 months after start of TB treatment. Inclusion of
PAXgene tube collection was initiated after the start of the
trial and therefore some participants did not have PAXgene
blood collected at all timepoints. Only those with at least two
PAXgene samples collected during TB treatment were included
in transcriptomic analyses. “Time to culture conversion” was
calculated by subtracting the date of the first positive MGIT
culture (BD Biosciences) result at diagnosis from the date
of the first persistent negative culture result and this “time
to culture conversion” was used to stratify patients into
early (conversion within 8 weeks) and late (conversion after
8 weeks) converters.
Diagnostic Cohort
In the third study, the Cross-sectional TB cohort (CTBC),
we assessed the impact of HIV-infection on the diagnostic
performance of the 11-gene ACS COR signature in an
observational study of HIV-infected (n = 40) and uninfected
(n = 60) South African adults from the Worcester region,
Western Cape. The study was designed to determine if the COR
signature could distinguish between Mtb infection and active TB
disease, diagnosed by a positive sputum Xpert MTB/RIF test.
Mtb infection was diagnosed by a positive QuantiFERON TB
Gold in-tube assay (Qiagen; cut-off >0.35 IU/mL). HIV-infection
was diagnosed with the Determine HIV1/2 test (Alere). Whole
blood was collected in PAXgene tubes and PBMC were isolated
from heparinized blood collected in Cell Preparation Tubes
(BD Biosciences). All participants provided written, informed
consent. The study protocol for the CTBC diagnostic study
was reviewed and approved by the Human Research Ethics
Committee of the University of Cape Town (HREC 761/2015).
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Ethics Statement
Prognostic Cohort
All participants of the previously completed TB Recurrence
upon Treatment with HAART (TRuTH) CAPRISA 005 study
(ClinicalTrials.gov, NCT01539005; SANCTR DOH-27-0909-
3040) provided written, informed consent in accordance with
the Declaration of Helsinki (Maharaj et al., 2017; Sivro et al.,
2017). The study protocol for TRuTH was reviewed and approved
by the University of Kwazulu-Natal Research Ethics Committee
(BREC No.: BF051/09).
Treatment Response Cohort
The “Improving Retreatment Success” trial (IMPRESS,
ClinicalTrials.gov, NTC02114684; SANCTR DOH-27-0414-
4576) was approved by the Medicines Control Council of
South Africa (MCC Ref:20130510) (Naidoo et al., 2017).
All participants provided written, informed consent in
accordance with the Declaration of Helsinki, and the study
protocol for IMPRESS was reviewed and approved by the
University of Kwazulu-Natal Research Ethics Committee
(BREC No. BFC029/13).
Diagnostic Cohort
The study protocol for the Cross-sectional TB cohort (CTBC)
diagnostic study was reviewed and approved by the Human
Research Ethics Committee of the University of Cape Town
(HREC 761/2015). All participants provided written, informed
consent, in accordance with the Declaration of Helsinki.
RNA Extraction and ACS COR Signature
Measurement
RNA was extracted from thawed cryopreserved PBMC samples
using the RNEasy plus Mini extraction kit (Qiagen) per
manufacturer’s instructions or from PAXgene samples using the
SimplyAmp extraction kit (Promega) using the Tecan Freedom
EVO 150 automated system. Expression of mRNA transcripts
comprising the 11-gene ACS COR signature (Darboe et al.,
2018) was measured using commercial TaqMan primer/probe
sets (Thermo Fisher Scientific; Supplementary Appendix A1)
by microfluidic qRT-PCR using 96.96 Gene Expression chips
(Fluidigm) on the Biomark HD multiplex instrument (Fluidigm)
after cDNA synthesis using Superscript II reverse transcriptase
(Invitrogen), as previously described (Zak et al., 2016). Signature
score data for the 11-gene ACS COR signature from the CTBC,
TRUTH and IMPRESS cohorts are available in Supplementary
Tables S1–S3. Signature scores for the 11-gene ACS COR
signature were calculated using in-house scripts written in R as
previously described (Zak et al., 2016; Darboe et al., 2018), and
provided as an Excel template (Supplementary Tables S4, S5).
Statistical Analyses
The pROC (Robin et al., 2013) and verification (Pocernich,
2015) R packages were used to calculate area under the receiver
operating characteristic (ROC) curve (AUC) and associated
95% confidence intervals (CI), and for comparing AUCs.
Medians and 95% CIs of relative differences in mRNA transcript
expression between groups (e.g., HIV-infected and uninfected
persons) were calculated using the rank inversion method
and bootstrapping 2,000 times using the quantreg R package
(Koenker, 1994). The Mann-Whitney U test was used to analyze
differences between groups. The Wilxocon signed rank test and
McNemar tests were used to compare continuous and binary
baseline characteristics, respectively, between progressors and
non-progressors in the TRuTH cohort. The Mann-Whitney U
test and the Chi-Square test were used to compare demographic





Among 520 participants in the longitudinal TRuTH study, 92
episodes of recurrent TB disease were recorded in 82 participants.
However, only 43 participants had sufficient cryopreserved
PBMC samples available for inclusion as progressors; 86 non-
progressors were selected for our transcriptomic analyses, for a
2:1 control:case matching (Figure 1A). No differences in age and
BMI at TRuTH enrolment were observed between progressors
and non-progressors (Table 1). Non-progressors had higher
median CD4 T-cell counts at baseline compared to progressors
[405 vs. 336, respectively (p = 0.01)]. A higher proportion of
virologically suppressed patients were non-progressors (88.2 vs.
62.8%; p < 0.001), most of whom completed TB treatment at
an earlier timepoint before TRuTH enrolment than progressors
(876 vs. 1079 days; p < 0.001). Recurrent TB disease occurred
at a median of 470 days (IQR: 250–672 days) after TRuTH
enrolment (Figure 2). All available samples from the progressors,
collected 6-monthly, were analyzed (Figure 2A), resulting in
103 progressor and 196 non-progressor samples that spanned
“time to recurrent TB” between 3 months and >2 years
before diagnosis (Figure 2B). CD4 T-cell counts, plasma viral
loads (pVL), and body mass index at the start of treatment
and end of treatment of the first TB episode are shown in
Supplementary Figure S1.
Treatment Cohort
A total of 197 newly diagnosed active TB cases with a previous
history of TB disease were enrolled into the IMPRESS trial
(Figure 1B). Most participants were HIV-infected (n = 139,
71%). Due to the low number of HIV-uninfected participants
with PAXgene samples available, only HIV-infected participants
were included in transcriptomic analyses. Among 115 HIV-
infected participants with any samples available, 70 participants
had PAXgene samples collected at baseline and two additional
study time-points and were eligible for inclusion into treatment
outcome analyses. Seven participants were excluded due
to protocol deviations related to treatment or absence of
culture results (Figure 1B), resulting in a final sample size
of 63 HIV-infected patients, 44 early converters and 19 late
converters (Figure 1B). Age, sex, proportion on anti-retroviral
therapy and plasma viral load were not different between
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FIGURE 1 | CONSORT of participant enrolment, allocation and analyses in the (A) TRuTH and (B) IMPRESS cohorts. Participants in the TRuTH study were
previously enrolled into either the SAPiT (Abdool Karim et al., 2010; Abdool Karim et al., 2011) or START (Gengiah et al., 2012) studies.
late and early converters (Table 2). However, late converters
had lower BMI and median CD4 T-cell counts than early
converters. A higher proportion of the late converters
included in our analyses were in the standard of care
arm, i.e., they received ethambutol and not moxifloxacin
(p = 0.01; Table 2).
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TABLE 1 | Demographic and clinical characteristics of progressors and non-progressors in the TRuTH study at study enrolment (prognostic cohort).
Participant characteristics Progressors (n = 43) Non-progressors (n = 86) p-value
Sex, n (%) Male 21 (49) 42 (49) 1.00
Median age, years (range) 35 (25–53) 37.5 (23–62) 1.00
Race, n (%) Black African 43 (100) 85 (99) 1.00
Other 0 (0) 1 (1)
Median BMI, kg/m2 (range) 24 (16.5–41.9) 24.3 (16.4–40.8) 0.58
Previous TB, n (%) 1 27 (62.8) 58 (67.4) 0.56
2 16 (36.4) 28 (32.6)
Median days since previous TB (range) 876 (707–2009) 1079 (706–1866) < 0.001
Median days on ART, (range)∗ 758 (-22–1988) 775.5 (-28–1803) 0.51
Plasma viral load (pVL), copies/mL∗∗ Undetectable, n (%) 35 (81.4) 79 (92.9) 0.01
Median of log dectectable pVL (range) 4.4 (2.8–5.7) 4.7 (3.8–6.0)
Median CD4 count (range), cells/µL 336 (14–884) 405 (66–1211) 0.01
∗Two non-progresors started ART after TRUTH enrollment and therefore excluded in this calculation. ∗∗Limit of detection of pVL was 400 copies/mL. Only 14 participants
had detectable pVL and no formal analysis of pVL magnitude was done.
Diagnostic Cohort
Fifty newly diagnosed active TB cases (20 of whom were
HIV-infected) and fifty Mtb infected persons (20 of whom
were HIV-infected) were enrolled into the CTBC. A higher
proportion of the HIV-uninfected active TB cases (73%) were
male in comparison to their Mtb-infected (27%) counterparts
(p = 0.0007). Mtb-infected HIV-uninfected individuals had a
higher BMI (median 30.4 vs. 20.5; p < 0.0001) and were older
(40.5 vs. 34, p = 0.01). No differences in the above characteristics
were observed between active TB and Mtb-infected controls who
were HIV-infected.
Prognostic Performance of 11-Gene ACS
COR Signature for Recurrent TB Disease
in HIV-Infected Persons on ART
We first determined the prognostic performance of the 11-
gene ACS COR signature for incident recurrent TB disease by
stratifying signature measurements into 1-year time windows
relative to TB diagnosis. Gene expression was measured using
RNA isolated from PBMC because whole blood RNA was not
available from the TRuTH study. We previously showed that
diagnostic performance of the 11-gene ACS COR signature
for TB disease was equivalent in RNA from whole blood and
PBMC, even though signature scores from PBMC were overall
significantly lower (Darboe et al., 2018).
Longitudinal kinetics of signature scores were highly
heterogeneous, although it is noteworthy that in a number of
progressors and non-progressors signature scores were high
at TRuTH enrolment and subsequently decreased during the
study (Figure 2C). No marked differences in signature scores
between progressors and non-progressors were apparent when
aligned according to time after study enrolment (Figure 2C)
or time to recurrent TB diagnosis (Figure 2D). Analysis of
prognostic performance by ROC AUC showed weak but
statistically significant (AUC 0.63, 95% CI 0.55–0.72, p = 0.003)
differentiation between progressors and non-progressors
using samples within 1 year of recurrence (Figure 2E). When
further stratified into 6-month windows, statistically significant
prognostic performance was only observed within 6 months of
TB diagnosis (AUC 0.68, 95% CI 0.57–0.79, p = 0.005); not in
the 6–12 months before window (AUC 0.58, 95% CI 0.45–0.71,
p = 0.23; Figure 2F). Interestingly, when samples in the 6-
month period immediately preceding recurrent TB were further
stratified into 3-month windows, only the samples collected
within 3 months of recurrence allowed stratification (AUC 0.72,
95% CI 0.58–0.85, p = 0.004; Figure 2G). These data suggest
that in ART-treated HIV-infected individuals with a previous
history of TB, prognostic performance of the 11-gene ACS COR
signature for recurrent TB was generally limited and only allowed
differentiation between progressors and non-progressors very
proximally to TB diagnosis. Since investigation for recurrent TB
entailed 3-monthly induced sputum it is likely that many cases
were diagnosed during subclinical stages of disease. Indeed, 25 of
the 43 recurrent cases (58%) were asymptomatic at the time of
microbiological diagnosis.
To put these findings into perspective, we benchmarked
them against the WHO target product profile (TPP) for a TB
risk test (World Health Organization [WHO], 2017a), which
should ideally be able to predict progression to TB within
2 years and provide a quantitative result that correlates with risk
of progression. Such a test should have a minimal specificity
of ≥75% and sensitivity ≥75% (World Health Organization
[WHO], 2017a). At a specificity of 75%, the sensitivity within
90 days of recurrent TB diagnosis was 60% and thus did not meet
the minimum criteria in the TPP (Table 3).
Utility of the 11-Gene ACS COR
Signature for TB Treatment Monitoring in
HIV-Infected Individuals
Next, we set out to determine if the 11-gene ACS COR signature
tracks host changes during TB treatment in HIV-infected TB
patients on ART with a history of previous TB using samples from
the IMPRESS cohort. Since the ACS COR signature detects ISG
expression we hypothesized that signature scores would decrease
by the end of TB treatment to reflect cure, as shown previously in
HIV-uninfected TB patients (Thompson et al., 2017). Signature
Frontiers in Microbiology | www.frontiersin.org 6 June 2019 | Volume 10 | Article 1441
fmicb-10-01441 June 26, 2019 Time: 15:57 # 7
Darboe et al. Transcriptomic TB Signature for HIV-Infected
FIGURE 2 | Study design and 11-gene ACS COR signature performance in the TRuTH study. Horizontal lines depict the 43 TRuTH cohort progressors and show
PBMC samples (black dots) collected in each individual. (A) TRuTH progressors aligned to their time of TRuTH study enrolment. The time of TB diagnosis is
indicated by the most left-hand end of each line (in red). (B) Re-alignment of TRuTH progressors and their samples according to each individual’s date of TB
diagnosis (on the right) to facilitate analyses of changes by “time to recurrent TB.” (C) 11-gene ACS COR signature scores at each participant visit for progressors
(red) and non-progressors (black), aligned by time since TRuTH enrolment. Inserts show the longitudinal kinetics of these scores for progressors (red, top) and
non-progressors (black, bottom). 90-day time windows relative to enrolment are depicted by the letters on the x-axis. (D) 11-gene ACS COR signature scores
realigned to time to recurrent TB diagnosis. (E–G) ROC AUCs depicting prognostic performance of the 11-gene ACS COR signature for recurrent TB, showing
discrimination of progressors from non-progressors in the TRuTH cohort. Each curve represents a 1-year (E), 6-month (F) or 3-month (G) time window prior to
recurrent TB diagnosis.
scores at TB diagnosis were high in the majority of cases and
decreased significantly at the end of the intensive phase, at month
two (Figure 3A). This was also evident from a negative change
in ACS COR signature score between these two timepoints in
62.8% of individuals (Figure 3B). Discrimination of the TB
treatment initiation and month two samples using the COR
signature was possible, but not impressive (AUC 0.63, 95% CI
0.52–0.74; Figure 3C). By the end of treatment most cases had
even lower scores, indicating an overall reduction in Type I/II
IFN inflammation (Figures 3A,B). This was also reflected by
better discrimination between TB treatment initiation and end
of treatment samples (AUC 0.80, 95% CI 0.71–0.88; Figure 3C).
We next determined if patients could be classified into early
and late converters based on their culture conversion status at
2 months of treatment. No marked differences were observed
in kinetics of median signature scores during treatment between
early and late converters, suggesting that the observed decrease
in COR signature scores after treatment initiation was not an
accurate predictor of early culture conversion in this study
cohort (Figure 3D).
ACS COR Signature, Sputum Conversion
and Time to Culture Positivity
Next, we wanted to establish if the COR signature could
differentiate early and late converters before or during TB
treatment in the IMPRESS cohort. We first determined if time
to sputum culture positivity at treatment baseline, a measure
of bacterial load, was associated with early culture conversion
(at 2 months). No difference in time to culture positivity
between early and late converters was observed at TB diagnosis
(Figure 4A). The 11-gene ACS COR signature, measured at
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TABLE 2 | Demographic and clinical characteristics of participants in the IMPRESS study (treatment response cohort).
Participant characteristic Entire cohort (n = 63) Early converters (n = 44) Late converters (n = 19) p-value
Sex, n (%) Male 44 (69.8) 28 (63.6) 16 (84.2) 0.10
Median age, years (range) 37 (19–51) 37 (21–51) 35 (19–51) 0.30
Race, n (%) Black African 62 (98.4) 43 (97.7) 19 (100) 0.51
Cape Mixed Ancestry 1 (1.6) 1 (2.3) 0 (0)
Median BMI, kg/m2 (range) 20.0 (15.6–37.8) 21.1 (16.6–37.8) 19.4 (15.6–26.1) 0.05
Study treatment arm, n (%) HRZM (Moxifloxacin) 33 (52.4) 28 (63.6) 5 (26.3) 0.01
On ARV∗, n (%) 28 (45.2) 19 (35.2) 9 (50) 0.76
Median CD4 counts∗∗, (range) 268 (46–849) 285 (46-849) 236.5 (69–477) 0.05
Plasma viral load ∗∗∗ Undetectable, n (%) 27 (45.0) 19 (45.2) 8 (44.4) 0.94
Median detectable pVL, log
copies/mL (range)
4.7 (2.8–6.1) 4.7 (3.3—6.1) 4.3 (2.8–5.6) 0.6
Limit of plasma viral load detection was set at 400 copies/mL. ∗Only 62 participants had data available, early converters (n = 44), late converters (n = 18). ∗∗Only 61
participants had CD4 count information; early converters (n = 43), late converters (n = 18). ∗∗∗Only 60 participants had plasma viral load data; early converters (n = 42),
late converters (n = 18).
TABLE 3 | Prognostic performance of the COR signature for recurrent TB disease in HIV-infected persons on ART, based on the TRuTH cohort.
Time to diagnosis Sensitivity Specificity Number needed to screen∗ False positives False negatives
WHO TPP (within 2 years of diagnosis), minimum characteristics > 75% > 75% 134 33 1
ACS COR signature 0–360 days 50% 75% 100 25 1
0–180 days 55% 75% 91 23 1
0–90 days 60% 75% 84 21 1
TTP, target product profile (World Health Organization [WHO], 2017a). ∗Number needed to screen to detect one case of TB. For these calculations a TB prevalence of
2% was used. False positives and negatives were calculated per number screened to detect one case of TB.
treatment baseline, also could not predict early conversion (AUC
0.46, 95% CI 0.39–0.72; Figure 4B); signature scores were also
not different (p = 0.49; Figure 4C). However, at the end of the
intensive phase of treatment (month two) the signature could
differentiate between early and late converters (AUC 0.73, 95%
CI 0.58–0.89; Figures 4B,C). This ability was lost by the end
of TB treatment (AUC 0.63, 95% CI 0.46–0.79; Figures 4B,C).
Furthermore, time to culture conversion was not correlated with
signature scores at treatment baseline (Figure 4D) and month
two of TB treatment (Figure 4E).
It was noted that signature scores remained relatively high at
the end of treatment, when all individuals had achieved clinical
cure. Markedly higher signature scores were also observed in
cured HIV-uninfected TB patients than matched healthy controls
in the previously published Catalysis for Health Foundation
(CHF) study (Thompson et al., 2017). We therefore sought
to determine if gene expression would decrease further after
clinical cure on the basis that residual inflammation may resolve
over time. A comparison of signature scores at the end of
treatment and a time point at least 6 months later showed no
significant changes (Supplementary Figures S2A,B); late and
early converters were also not different at these late follow-up
time points (Supplementary Figures S2C,D).
Effect of HIV on Diagnostic Performance
of the 11-Gene ACS COR Signature
Prognostic performance of the 11-gene ACS COR signature in
the TRuTH study was poorer than expected from the previous
studies in HIV-uninfected cohorts (Zak et al., 2016; Darboe et al.,
2018; Suliman et al., 2018). Similarly, the observed reduction
in signature score during treatment in the IMPRESS trial was
less marked than was observed in the HIV-uninfected CHF
study (Thompson et al., 2017). In light of these results and the
well-established evidence that HIV infection is associated with
elevated levels of plasma type I IFN protein and expression levels
of ISGs in peripheral blood cells (Bosinger and Utay, 2015),
we hypothesized that specificity of the ISG-based ACS COR
signature would be lower in HIV-infected persons due to higher
signature scores. To address this, we compared the diagnostic
performance of the signature for discriminating between TB
cases and Mtb-infected controls in HIV-infected (20 cases and 20
controls) and HIV-uninfected (30 cases and 30 controls) adults
from the CTBC. Diagnostic performance in HIV-uninfected
persons was excellent; AUCs of 0.97 (95% CI 0.94–1) and 0.98
(95% CI 0.95–1) were observed when whole blood or PBMC
samples were tested, respectively (Figures 5A,B). However, in
HIV-infected persons a striking reduction in AUC values was
observed (whole blood AUC 0.83, 95% CI 0.81–0.96; PBMC AUC
0.88, 95% CI 0.78–0.99; Figures 5A,B). To understand these
figures within the context of a desired triage test for TB, we
benchmarked these against the WHO TPP for a triage test (World
Health Organization [WHO], 2014). At a specificity of 80%, the
COR signature achieved a sensitivity of 100% in HIV-negative
and of 65% in HIV-infected persons (Table 4). These figures
suggest that fewer HIV-infected people would have to be screened
with the COR signature to detect a TB case compared with the
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FIGURE 3 | TB treatment response monitoring in the IMPRESS cohort using the 11-gene ACS COR signature. (A) 11-gene ACS COR signature scores before
(baseline), during (after intensive phase, at 2 months) or after treatment of recurrent TB in the IMPRESS study. (B) Differences in signature scores at 2 months or end
of treatment relative to treatment baseline. Red dots represent individuals with sputum culture conversion after 2 months (late converters) and blue dots individuals
with culture conversion before 2 months (early converters). Horizontal lines represent medians and error bars the inter-quartile ranges (IQR). p-values were calculated
using the Wilcoxon matched pairs test. (C) ROC AUCs depicting signature discrimination between baseline and month two or end of treatment samples.
(D) Longitudinal kinetics of median signature scores during TB treatment in early and late converters. Error bars represent the IQR.
current methods of symptom screening or symptom screening
plus chest radiography (Getahun et al., 2011; Table 4).
Comparison of the quantitative signature scores showed a
highly significant increase in HIV-infected relative to HIV-
uninfected Mtb-infected controls (but not TB cases), suggesting
markedly elevated ISG-expression due to underlying HIV
infection (Figures 5C,D). To determine if this is driven by a
subset of mRNA transcripts in the signature, we computed the
median and 95% CI of the difference in individual transcript
expression between HIV-infected and uninfected persons.
Expression of most transcripts was significantly elevated in
HIV-infected individuals relative to HIV-uninfected individuals
(indicated by a negative difference in delta Ct value), irrespective
of TB status or RNA source (Figures 5D,E), confirming that HIV
infection elevated ISG expression. Interestingly, some STAT1
and SCARF1 transcripts were expressed at lower levels in HIV-
infected than in HIV-uninfected persons, opening the possibility
that a signature with more tolerance for HIV could be developed.
Next, we sought to investigate the role of HIV plasma viral
load (pVL) on the transcriptomic ACS COR signature. In light
of our results above, we hypothesized that signature scores are
associated with pVL. Analysis of pVL as a continuous variable
was complicated by the fact that most participants in the
TRuTH and IMPRESS studies were on long-term ART and had
suppressed pVL. Regardless, pVL were detectable at some time
points and stratification of signature scores by detectable (>400
copies/mL) and undetectable (<400 copies/mL) pVL showed
significantly elevated scores for samples with detectable pVL in
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FIGURE 4 | Classification of late and early sputum culture converters in the IMPRESS cohort. (A) Pre-treatment time to MGIT culture positivity for IMPRESS
participants with sputum culture conversion before 2 months (early converters) or with sputum culture conversion after 2 months (late converters). (B) ROC AUCs
depicting 11-gene ACS COR signature discrimination between early and late sputum culture converters at baseline, month two or end of treatment. (C) 11-gene
ACS COR signature scores for early and late sputum culture converters at baseline, month two or end of treatment. p-values were calculated using the
Mann-Whitney U test. (D,E) Association between signature scores and time to liquid culture positivity at baseline (D) and 2 months after treatment start (E).
the TRuTH (Figure 6A) and IMPRESS (Figure 6B) cohorts. In
the TRuTH cohort ACS COR signature scores were also weakly
associated with quantitative levels of pVL > 400 copies/mL
(Spearman ρ = 0.40, p = 0.04; Figure 6C).
Finally, we determined if prognostic signature performance in
the TRuTH cohort was influenced by pVL. Only 27 samples had
detectable pVL, precluding analysis of signature performance in
this subset. We therefore compared prognostic performance in
all samples within 6 months of recurrent TB diagnosis or only
those in this time window with undetectable pVL. Prognostic
performance of the signature for recurrent TB disease was
equivalent when all samples or only those with undetectable pVL
were included (0–3 months before TB, AUC of 0.72 (95% CI 0.58–
0.85) for all and AUC 0.71 (95% CI 0.55–0.85) for pVL <400
copies/mL; Figure 6D).
DISCUSSION
Blood transcriptomic signatures of TB risk show promise as
non-sputum triage tests for TB, identification of individuals
with incipient or subclinical disease who are at high risk of
developing active TB disease (prognostic performance) and as
tools for monitoring treatment outcome. However, prognostic
performance of risk signatures in HIV-infected individuals who
are at very high risk of TB, has not been specifically and
comprehensively assessed. In the present study we determined
the prognostic performance for incident recurrent TB, diagnostic
performance and utility for TB treatment monitoring of the
11-gene transcriptomic ACS COR signature in HIV-infected
individuals on ART.
We found that among HIV-infected individuals on ART
the transcriptomic COR signature had limited prognostic value
and only significantly differentiated between recurrent TB
progressors and non-progressing controls within 3 months
of disease diagnosis. This is markedly inferior to prognostic
performance in the HIV-uninfected adolescent study, where
the ACS COR signature differentiated significantly between
progressors and non-progressors 1–1.5 years before TB diagnosis
(Zak et al., 2016). These results, as well as broader transcriptomic,
proteomic and cellular analyses of the adolescent progressors
(Scriba et al., 2017), suggest that the ACS COR signature detects
ISG expression during incipient and/or subclinical disease, many
months before symptom manifestation. Since investigation for
TB in the TRuTH cohort was based on sputum induction at
every visit on every participant, we propose that the resultant
early detection of disease during subclinical stages may have
impeded the prognostic performance within the confines of
the TRuTH study. Indeed, 58% of the 43 recurrent cases were
asymptomatic at the time of diagnosis. Interestingly, a number
of these asymptomatic cases (n = 25) refused TB treatment and
subsequently developed TB symptoms. Detection of subclinical
disease is not unexpected since prevalence of asymptomatic
TB, defined as disease without clinical TB related symptoms
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FIGURE 5 | Effect of HIV on diagnostic performance of 11-gene ACS COR signature. (A,B) ROC curves depicting 11-gene ACS COR signature discrimination
between Xpert MTB/RIF+ TB cases and QFT+ Mtb-infected controls in HIV-uninfected (black lines) and HIV-infected (red lines) diagnostic performance of the
signature when measured from whole blood (A) or PBMC (B). (C,D) 11-gene ACS COR signature scores from HIV-infected (red) and uninfected (black) TB cases (TB
disease) or Mtb-infected controls (QFT+), when measured in whole blood (C) or PBMC (D). Horizontal lines represent medians, boxes represent the IQR and
whiskers represent ranges. (E) Differences in expression of individual transcripts comprising the 11-gene ACS COR signature between HIV-uninfected and
HIV-infected individuals, stratified into TB cases (red) and Mtb-infected controls (black), when measured in whole blood (top) or PBMC (bottom). Transcripts are
identified by their TaqMan primer set reference (see Supplementary Appendix A1). Dots represent medians and error bars 95% CI for each transcript, computed
from delta-Ct (qRT-PCR cycle threshold) values with the rank inversion method and bootstrapping 2000 times. Negative differences indicate higher expression in
HIV-infected individuals relative to HIV-uninfected individuals. We considered transcripts for which the 95% CI bounds do not overlap with zero (dashed horizontal
line) to be significantly different.
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TABLE 4 | Performance of the COR signature as a triage test in HIV-infected and uninfected persons based on results from our diagnostic cohort.
HIV status Sensitivity Specificity Number needed to screen∗ False positives False negatives
WHO TTP for Triage test, optimal characteristics > 95% > 80% < 55 < 11 1
ACS COR signature HIV-uninfected 100% 80% 50 10 0
ACS COR signature HIV-infected 65% 80% 77 16 1
Performance of current screening tools in HIV-infected persons
Symptom screening only∗∗ 79% 50% 64 32 1
Symptom screening and chest radiography∗∗ 91% 39% 55 33 1
TTP-Target product profile (World Health Organization [WHO], 2014). ∗Number needed to screen to detect one case of TB. For these calculations a TB prevalence of 2%
was used. False positives and negatives were calculated per number screened to detect one case of TB. ∗∗Estimates for symptom screening and chest radiography are
based on results from Getahun et al. (2011).
FIGURE 6 | Effect of HIV plasma viral load (pVL) on 11-gene ACS COR signature scores. (A) 11-gene ACS COR signature scores in samples from the TRuTH cohort
stratified by detectable pVL (>400 copies/mL, n = 27) and undetectable pVL (<400 copies/mL, n = 253). Horizontal lines depict medians and error bars IQRs.
(B) 11-gene ACS COR signature scores in samples from the IMPRESS cohort stratified by detectable pVL (n = 36) and undetectable pVL (n = 50). (C) Spearman
correlation analysis between signature scores and quantitative pVL for samples with detectable pVL in the TRuTH cohort (n = 27). (D) ROC AUC depicting
prognostic performance of the 11-gene ACS COR signature for discriminating between progressors and non-progressors from the TRuTH study when considering
all samples in the depicted time windows or only samples with undetectable pVL.
but with abnormalities that can be detected with radiologic or
microbiological tests, is generally high in studies that perform
active case finding in high-risk populations (Drain et al., 2018).
For example, in a review of 12 national TB prevalence surveys
in Asia, 40–79% of microbiologically-confirmed TB cases were
asymptomatic (Onozaki et al., 2015). In addition, there is
Frontiers in Microbiology | www.frontiersin.org 12 June 2019 | Volume 10 | Article 1441
fmicb-10-01441 June 26, 2019 Time: 15:57 # 13
Darboe et al. Transcriptomic TB Signature for HIV-Infected
some evidence that HIV-infected persons may progress more
rapidly to TB disease than HIV-uninfected persons (Fitzgerald
et al., 2000; Mallory et al., 2000; Charalambous et al., 2008;
Drain et al., 2018), which may also account for the reduced
prognostic performance observed in the TRuTH study. Despite
this limited performance of the signature and low sensitivities at
the specificity cut-off target of >75% in the WHO TPP (World
Health Organization [WHO], 2017a), the number of people
needed to screen to detect a TB case still fell below the minimum
target, while also yielding fewer false positives than the target
(Table 3). By contrast, tests like the AlereLAM and the new
generation FujiLAM are unlikely to have prognostic utility, and
application in HIV co-infected individuals beyond those with
dramatically low CD4 T cell counts remains to be investigated
(Maclean et al., 2019). One other study, by Sloot et al. (2015)
reported a 2-gene signature comprising IL-13 and AIRE that
correlated with TB disease risk in a small cohort of 15 HIV-
infected drug users who developed active TB disease and 16
who did not develop TB. Unfortunately this 2-gene signature
was not externally validated and thus the true performance
of this highly parsimonious signature in an external cohort is
currently unknown.
Provision of isoniazid prophylaxis to HIV-infected individuals
typically decreases the risk of progression to active TB disease,
but studies in endemic settings have shown that TB incidence
increases shortly after cessation of isoniazid prophylaxis (Golub
et al., 2015; Samandari et al., 2015). In the TRuTH study
20 progressors and 37 non-progressors received 6 months of
isoniazid during follow-up (Maharaj et al., 2017). We did not
adjust the time-at-risk in our analyses to account for effects on
INH prophylaxis, but it was noteworthy that most progressors
who developed recurrent TB disease were diagnosed within a
few months (median of 279 days) of stopping INH prophylaxis
(Maharaj et al., 2017). The effect of isoniazid prophylaxis may
also have contributed to the poor prognostic performance of
the ACS COR signature. Taken together, these findings highlight
the importance of clear guidelines on appropriate screening and
treatment strategies for latent infection and subclinical disease in
HIV-infected persons.
We and others have shown that transcriptomic signatures
may be useful to monitor treatment outcome in HIV-uninfected
persons (Berry et al., 2010; Bloom et al., 2013; Sweeney
et al., 2016; Thompson et al., 2017). In the present study
we show that transcriptomic COR signature scores decreased
significantly during TB treatment in IMPRESS patients, all
of whom had clinical cure. However, signature discrimination
between those with sputum culture conversion at 2 months of
treatment was only possible at the 2-month time point, not
at treatment initiation or end of treatment. It was noteworthy
that cured patients retained high signature scores, consistent
with elevated type I/II IFN responses up to 8 months after
the end of TB treatment in the IMPRESS cohort. This finding
is consistent with the observation of high transcriptomic COR
signature scores at the end of TB treatment and up to a
year after successful cure in the HIV-uninfected Catalysis for
Health Foundation study participants (Thompson et al., 2017).
These data, supported by persistent pulmonary inflammation
detected on PET-CT and detection of mycobacterial RNA
in bronchoalveolar lavage samples, are suggestive of residual
disease or mycobacterial survival after successful cure (Malherbe
et al., 2016). However, underlying inflammation resulting
from HIV infection as well as low-level HIV replication,
also likely contributed to elevated signature scores in the
IMPRESS patients. Since the IMPRESS trial was performed
in a high Mtb-transmission setting we cannot rule out that
reinfection after cure may also have contributed to elevation of
signature scores.
Taken together, our findings show that diagnostic, prognostic
and treatment monitoring utility of the 11-gene transcriptomic
COR signature were reduced in these HIV-infected cohorts
compared with studies in HIV-uninfected individuals. Our
study suggests an approximately 10% reduction in diagnostic
performance in HIV-infected compared to HIV-uninfected
persons, although the sample size of our study limits the
strength of this finding. Nevertheless, this is in line with other
studies, which also report reduced diagnostic performance of
largely ISG-based transcriptomic signatures for TB disease in
HIV-infected populations, relative to HIV-uninfected persons
(Kaforou et al., 2013; Dawany et al., 2014; Sweeney et al.,
2016; Walter et al., 2016; Zak et al., 2016). Our results
suggest that the reduction in signature performance in the
HIV-infected cohort is attributable to higher signature scores
in those without incipient, subclinical or active disease.
Regardless, diagnostic performance was still superior to symptom
screening alone or symptom screening in parallel with chest
radiography in HIV-infected persons (Getahun et al., 2011).
Several other studies have also reported diagnostic performance
of transcriptomic signatures in HIV-infected cohorts, including
a large signature based on 251 transcripts (Dawany et al.,
2014) and another one based on the single gene, BATF2 (Roe
et al., 2016). We were not able to perform direct comparisons
of the performance of the our 11-gene transcriptomic COR
signature with these because this would have to be done in
the same cohort. This highlights the importance of directly
comparing the multiple published transcriptomic signatures
directly in diverse cohorts. Notably, a very recent study
performed such a systematic comparison of the diagnostic
performance of 16 published transcriptomic signatures in 24
publicly available microarray or RNA-sequencing datasets and
reported that a 3-gene signature performed best (Warsinske
et al., 2019). It will be important to perform prospective
clinical validation of such signatures in future studies and
also to assess prognostic performance of these signatures
for incident TB.
We also showed that detectable pVLs were associated with
elevated transcriptomic COR signature scores and expression
of many individual ISG transcripts comprising the signature
were higher in HIV-infected compared with HIV-uninfected
individuals. This is consistent with well-established evidence
that HIV infection is associated with elevated levels of plasma
type I IFN protein and ISG expression in peripheral blood cells
(Bosinger and Utay, 2015). Our data suggest that transcriptomic
signatures for TB that are discovered or parameterized in HIV-
infected cohorts may yield better diagnostic performance in
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HIV-infected individuals than signatures developed in HIV-
uninfected populations. Signatures developed by multi cohort
analyses that included HIV-infected and uninfected individuals
provide clues that such signatures may be more tolerant to
the effects of underlying HIV infection [11, Duffy et al.,
under review]. Alternatively, transcripts known to be elevated
in HIV-infected individuals, such as ISGs, may have to be
explicitly excluded from transcriptomic signatures for HIV-
infected individuals. Such a strategy was employed by Esmail
et al. (2018) who identified a signature of subclinical TB in HIV-
infected individuals, which comprised transcripts representing
the classical complement pathway and FcγR signaling. Such
a signature might equally perform well in HIV-uninfected
persons. A single, “universal” signature for both HIV-infected
and uninfected populations would be more feasible for
implementation as a triage test in community health settings. It is
not well understood if geographic, epidemiological or population
genetics differences are likely to impact overall performance
and utility of such a signature. The COR signature, which was
derived in South African adolescents, validated with similar
prognostic performance in the adult household contacts of
the GC6-74 study from The Gambia and South Africa (Zak
et al., 2016), although prognostic performance of the same
signature in the much smaller GC6-74 test sets of Gambian
and Ethiopian household contacts was not significant (Suliman
et al., 2018). Notably, no modification of the COR signature
was made in our study when applying it as a diagnostic,
prognostic or treatment monitoring tool. The demonstrated
application to cryopreserved PBMC allows broader opportunities
for validation in non-African cohorts in the future, if such
biobanks are available.
Our analyses were limited by relatively small cohort sizes
and were not sufficiently powered to investigate signature
performance as a function of pVL quantitative levels. Regardless,
our stratification by detectable and undetectable pVL clearly
showed a strong effect on signature scores and represents, to the
best of our knowledge, a first attempt at delineating effects of HIV
load on TB transcriptomic signatures. We acknowledge that a
pVL assay with lower limit of detection may have allowed greater
ability to interrogate the effects of VL below 400 copies/mL on
the COR signature.
We also acknowledge that healthy individuals with latent
infection are not the ideal control group for establishing
diagnostic performance of a triage test. Future studies that assess
diagnostic performance should also include control groups of
symptomatic individuals who do not have TB but present with
other respiratory diseases. We did not have access to such control
“other disease” participants in our study.
CONCLUSION
In conclusion, the transcriptomic ACS COR signature showed
good diagnostic performance for TB disease, modest prognostic
performance for recurrent TB and modest utility for TB
treatment monitoring in HIV-infected individuals on ART. Our
results suggest that underlying HIV infection has a marked
effect on performance of ISG-based transcriptomic signatures,
which requires further investigation in larger studies. Prospective
studies of the diagnostic and prognostic performance of the
transcriptomic ACS COR signature in both HIV-uninfected and
HIV-infected persons is currently underway at five clinical sites
in South Africa (ClinicalTrials.gov, Identifier: NCT02735590).
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FIGURE S1 | Clinical and demographic characteristics of TRuTH study
participants at primary TB treatment in the SAPiT or START studies (A–C), end of
primary TB treatment (D,E) and at TRuTH enrolment (F).
FIGURE S2 | 11-gene ACS COR signature scores after TB treatment in the
IMPRESS cohort. (A) Comparison of signature scores at the end of treatment and
6–8 months later in the IMPRESS cohort. Red dots represent individuals with
sputum culture conversion after 2 months (late converters) and blue dots
individuals with culture conversion before 2 months (early converters). Horizontal
lines represent medians and error bars the IQR. p-values were calculated using
the Mann-Whitney U test. (B) ROC AUC depicting 11-gene ACS COR signature
discrimination between end treatment samples and samples collected
6–8 months later. (C) ROC AUC depicting 11-gene ACS COR signature
discrimination between early and late sputum culture converters 6–8 months after
end of TB treatment. (D) Signature scores for early and late converters
6–8 months after end of TB treatment. Horizontal lines represent medians and
error bars the IQR and p-values were calculated using the Mann-Whitney U test.
TABLE S1 | 11-gene COR signature scores in CTBC participants.
TABLE S2 | 11-gene COR signature scores in TRUTH participants.
TABLE S3 | 11-gene COR signature scores in IMPRESS participants.
TABLE S4 | Worksheet for entry of raw Ct values from the qRT-PCR assay.
TABLE S5 | Worksheet that calculates risk scores upon input of raw Ct values.
APPENDIX A1 | Genes and primer-probe IDs of transcripts in the ACS CoR
11-gene signature.
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